Category: Renal
Renal
NxStage Medical Inc. continued its positive trend of increased sales and lower losses, posting a nearly 21 percent boost to its top line and reducing losses by 34 percent.
NxStage Medical Inc. (NSDQ:NXTM) took another leap along the path to profitability during the second quarter, posting a 20.9 percent revenues increase and shaving losses by 34 percent.
The Lawrence, Mass.-based home hemodialysis products maker reported net losses of $8.3 million, or 17 cents per diluted share, on sales of $44.0 million during the three months ended June 30. That compares with net losses of $12.5 million, or 27 cents per diluted share, during the same period last year.
PharmacoPhotonics Inc. drums up $1.5 million in an equity offering to develop a device that measures kidney function.
By Brandon Glenn
PharmacoPhotonics Inc. raised $1.5 million in equity to develop a device that measures kidney function.
The company’s device can provide a measure of the kidney’s function, or glomerular filtration rate, in 15 to 30 minutes. Current methods of determing GFR either provide a rough estimate or require collecting a patient’s urine samples over a 24-hour period.
CytoPherx Inc. raises $11.7 million in equity, debt and options to develop a device that filters the blood of kidney-disease patients.
By Brandon Glenn
CytoPherx Inc. raised $11.7 million for the development of a device that filters the blood of kidney-disease patients.
The Ann Arbor, Mich.-based company is creating hollow-fiber dialysis filters, which doctors use to isolate and deactivate white blood cells in a patient's circulatory system. The company focuses on treating diseases and conditions such as renal failure and inflammation caused by cardiopulmonary bypass surgery.
Hemosphere Inc. hires former St. Jude Medical Inc. sales and marketing leader Patrick Wethington as its new chief executive.
By Brandon Glenn
Hemosphere Inc., which sells a vein-access device for chronic kidney disease patients, has hired a former St. Jude Medical (NYSE:STJ) sales and marketing leader as its new chief executive.
Patrick Wethington spent about 10 years with St. Jude before his most recent post, vice president of sales and marketing at Sweden-based Gambro Inc., which also sells medical technology aimed at patients with kidney problems.
Pluromed Inc. drums up $1.1 million toward its $3.9 million Series C funding goal from a group of 16 investors.
Pluromed Inc. raised $1.1 million, nearly a third of its $3.9 million Series C goal, from a group of 16 un-named investors.
The Woburn, Mass.-based company has netted nearly $8.3 million so far, about $2.5 million from its Series A round and $4 million and $741,000 from two Series B tranches, according to filings with the federal Securities and Exchange Commission.
The U.S. Patent and Trademark Office issues notices of allowance to PLC Systems for a pair of patents covering the company's RenalGuard technology.
PLC Systems Inc. (OTC:PLCSF) got some badly-needed good news when the U.S. Patent and Trademark Office issued notices of allowance for a pair of patents covering the Franklin, Mass.-based company's RenalGuard technology.
The USPTO issues a notice of allowance after determining that an applicant is legally entitled to a patent. PLC said it expects to win its two patents later this year, according to a press release.
Hemosphere CEO Doris Engibous on her move from corporate life to leading a small start-up and what sets the company's hemodialysis products apart.
By Brandon Glenn
After more than 20 years in corporate America, Doris Engibous says she was “big-companied out.”
So the medical technology veteran jumped at the opportunity to move from California to Minnesota six years ago to become a first-time CEO for Hemosphere Inc., which has developed a vein-access device for chronic kidney disease patients who need hemodialysis.
